Table 1.
Demographic features of autoimmune pulmonary alveolar proteinosis (aPAP) patients at baseline
| Parameter | Control group (n = 17) |
Treatment group (n = 19) | P value | |
|---|---|---|---|---|
| Age (year) | 42.88 ± 12.75 | 43.53 ± 12.89 | 0.881 | |
| Sex (female/male) | 4/13 | 6/13 | 0.717 | |
| Duration of the disease (months)a | 6 (6–60) | 6 (0.5–60) | 0.852 | |
| Smoking status | Never | 7 | 7 | 0.965 |
| Ex-smoker | 5 | 6 | ||
| Current smoker | 5 | 6 | ||
| Disease Severity Score | 1 | 0 | 0 | 0.409 |
| 2 | 13 | 11 | ||
| 3 | 4 | 8 | ||
| Hb (g/dL) | 16.11 ± 1.61 | 16.00 ± 1.64 | 0.839 | |
| HCT (%) | 46.07 ± 3.7 | 45.74 ± 4.47 | 0.810 | |
| LDH (U/L) | 244.06 ± 53.02 | 233.82 ± 43.43 | 0.547 | |
| CEA (U/L) | 5.34 ± 4.96 | 4.74 ± 3.41 | 0.678 | |
| FEV1 pred (%) | 78.09 ± 14.12 | 79.16 ± 15.68 | 0.832 | |
| FVC pred (%) | 79.14 ± 13.42 | 79.71 ± 13.70 | 0.900 | |
| TLC pred (%) | 74.59 ± 9.65 | 74.82 ± 10.78 | 0.946 | |
| DLCO pred (%) | 69.50 ± 13.94 | 68.41 ± 16.90 | 0.835 | |
| DLCO/VA pred (%) | 98.58 ± 18.45 | 98.67 ± 24.32 | 0.990 | |
| PaO2 (mmHg) | 77.51 ± 8.53 | 76.88 ± 11.23 | 0.854 | |
| A-aDO2 (mmHg) | 28.32 ± 9.09 | 28.74 ± 11.04 | 0.902 | |
| SGRQ symptom | 24.06 ± 13.55 | 29.17 ± 29.75 | 0.506 | |
| SGRQ activity | 30.70 ± 18.46 | 30.33 ± 16.55 | 0.949 | |
| SGRQ effect | 24.20 ± 16.10 | 21.83 ± 21.29 | 0.712 | |
| SGRQ total | 26.47 ± 14.74 | 27.38 ± 19.75 | 0.878 | |
| 6MWD | 495.25 ± 79.39 | 477.95 ± 65.68 | 0.485 | |
| SpO2 at the end of 6MWD | 94.87 ± 2.70 | 94.58 ± 5.20 | 0.847 | |
| Mean lung density | − 718.62 ± 82.70 | − 687.25 ± 68.48 | 0.315 | |
| Total lung volume radiological measurement (ml) | 4556.08 ± 841.15 | 4461.08 ± 1399.60 | 0.841 | |
| GM-CSF antibody (μ g/ml) | 75.86 ± 93.94 | 73.30 ± 58.65 | 0.922 | |
| Treatment before the trial | Never | 13 | 14 | 0.489 |
| WLL | 3 | 5 | ||
| Othersb | 1 | 0 | ||
Abbreviations: aPAP autoimmune pulmonary alveolar proteinosis, A-aO2 alveolar arterial oxygen gradient, CEA carcinoembryonic antigen, DLCO: DLCO: diffusing capacity for carbon monoxide, DLCO/VA diffusing capacity for carbon monoxide corrected for alveolar volume, FEV1 forced expiratory volume in the first second, FVC forced vital capacity, GM-CSF granulocyte macrophage colony stimulating factor, Hb hemoglobin, HCT hematocrit, LDH lactate dehydrogenase, PaO2 partial pressure of oxygen, SGRQ St George Respiratory Questionnaire, SpO2 oxygen saturation in pulse oximetry, TLC total lung capacity, 6MWD 6 min walking distance (test)
a: median (inter-quartile range)
b:Traditional medicine treatment